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A 41-year-old patient was referred with proteinuria and a
recent rise in serum creatinine from 1 to 1.5 mg/dl. The
patient’s history was significant for recurrent alcoholic
pancreatitis and a myocardial infarction 8 years earlier when
he was diagnosed to be HIV- and hepatitis B-positive. The
patient had a history of nocturia for 5 years and frothy urine
for 1 year but denied any diarrhea. His medication regimen
for the past 4 years consisted of emtricitabine, tenofovir,
atazanavir, and ritonavir (for HIV and Hepatitis B coinfec-
tion) as well as enalapril and atenolol. Physical examination
was unremarkable and his blood pressure was 104/65 mm Hg.
Laboratory studies showed (in mmol/l) Na 143, K 3.8, Cl 110,
CO2 21, and a BUN 18 mg/dl, blood pH of 7.349, blood
glucose of 92 mg/dl, serum phosphate 2.4 (reference range:
2.7–4.5 mg/dl), uric acid 3.6 (reference range: 3.6–7.7 mg/dl),
normal complement levels and negative ANA, ANCA and
rheumatoid factor. Urinalysis by dipstick showed a pH 5.0,
1þ protein, 1þ blood, and 1þ glucose. A 24-h urine
collection (3 l) had 1.86 g of protein, 0.34 g of albumin, and
1.9 g creatinine. Serial laboratory tests are shown in Table 1.
Urine sediment microscopy performed on the day of the
renal biopsy showed 0–1 RBC, 0–1 WBC, 4–5 renal epithelial
cells (some cigar shaped)/high-power field (Figure 1), with
5–6 fine granular casts/low-power field. No oval fat bodies or
eosinophils were identified. Kidneys were normal in size and
echotexture on ultrasonography.
What is the cause of the patient’s renal dysfunction?
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Figure 1 |Thin smear of urine sediment stained with modified
Wright stain (Hansel’s stain) showing cigar shaped renal
epithelial cells. (Original magnification 400).
Table 1 | Laboratory results noted on chart review
2004 2006 2007 2009
Serum creatinine (mg/dl) 1.1 0.9 1.0 1.5
Serum albumin (g/dl) 3.6 3.8 3.8 4.9
Serum protein (g/dl) 6.4 6.1 6.3 7.8
Cholesterol (mg/dl) 138 130 176 116
Urinalysis
Protein Trace 1+ 1+ 2+
Glucose Negative Negative 2+ 2+
Blood Negative Trace Trace Trace
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The Diagnosis | Tenofovir toxicity
This patient appears to have developed proximal tubular
dysfunction that was first evidenced by the presence of
orthoglycemic glycosuria, that is, glycosuria with a normal
blood glucose that developed approximately 2 years after
being initiated on therapy with the nucleotide reverse
transcriptase inhibitor, tenofovir. On further investigation,
the patient was noted to have a low normal serum phosphate
(2.4 mg/dl) with high fractional excretion of phosphate (35%,
range: 5–20%), low normal serum uric acid (3.6 mg/dl) with
high fractional excretion of uric acid (30%, range: 6–12%),
and a normal anion gap metabolic acidosis with a urine pH
of 5.0. Further urine studies showed evidence of significant
proteinuria, of which only 16% was albuminuria, which
suggested a tubular source of the proteinuria. This was
further supported by the high urinary b2-microglobulin
(73 mg/g of creatinine) and presence of generalized amino
aciduria. This constellation of blood and urinary derange-
ments coupled with the proximal tubular epithelial cells in
the urinary sediment is consistent with proximal tubular
injury and Fanconi syndrome—likely secondary to tenofovir.
Renal biopsy revealed toxic acute tubular necrosis predomi-
nantly involving proximal tubules, consistent with tenofovir
toxicity.
Fanconi syndrome is the result of either an inborn error of
metabolism or the result of a tubular toxicity. Drug-induced
renal Fanconi syndrome is not uncommon and has been
reported with several antiretroviral medications, including
tenofovir, and consists of a generalized tubular dysfunction
that is associated with a decreased net proximal reabsorption of
glucose, amino acids, phosphate, bicarbonate, and uric acid.1,2
Although prospective clinical trials have demonstrated a
low incidence of renal toxicity with tenofovir, there are
several such reports in the literature, starting in 2002.2,3 The
first tenofovir-related renal toxicity case described Fanconi
syndrome, acute renal failure, and nephrogenic diabetes
insipidus temporally associated with the use of the drug that
improved with drug cessation.2 Tenofovir has been shown to
cause renal proximal tubular mitochondrial ultrastructural
abnormalities that parallel mitochondrial DNA depletion in
the same cells.4 Although the exact mechanism of tubular
injury associated with tenofovir remains unclear, the risk of
injury is likely to be multifactorial. Risk factors include older
age, lower weight, and concomitant medications such as
ritonovir.5 Current recommendations suggest close monitor-
ing of renal function after initiation of therapy with
tenofovir, especially early on and when used in combination
with certain other antiretroviral agents.2
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